Drugs / JNJ-95566692
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07308132 | Jan 2026 → Aug 2028 expected | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-95566692 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07308132 ↗ |
| Route | Subcutaneous | “JNJ-95566692 will be administered subcutaneously.” NCT07308132 ↗ |